Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanosonics Limited (NAN.AX)
AUD3.21
-0.01 (-0.31%)
AU ASX Healthcare Medical - Instruments & Supplies
Address
Building A 2113
Macquarie Park, NSW, AU
Macquarie Park, NSW, AU
CEO
Michael C. Kavanagh
Website
nanosonics.com.au
IPO
2007-05-17
ISIN AU000000NAN9
Also trades on
Australian Securities Exchange · NAN.AX (AUD)
Other OTC · NNCSF (USD)
Description
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD3.21
-0.01 (-0.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
702.2K
Beta
1.22
Float Shares
255.71M
Free Float %
85.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.94% | -5.39% | -8.93% | -7.60% | -26.17% | -20.40% | -29.15% | -37.05% | -43.06% | +31.12% | +285.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.21
DCF (Unlevered)
2.29
-28.8%
DCF (Levered)
4.75
+48.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
63% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
12.54
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+16.0% ★ Q4'25: +27.1% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+59.3% ★ Q4'25: +54.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.1% ★ Q4'25: +4.2% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+11.9% Q4'25: +8.5% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+39.1% ★ Q4'25: +45.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q4'25: +1.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.24× ★ Q4'25: 0.19× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 8 Rev. Ana. 6 EPS Ana. |
Jun 2027 8 Rev. Ana. 6 EPS Ana. |
Jun 2028 8 Rev. Ana. 6 EPS Ana. |
Jun 2029 6 Rev. Ana. 3 EPS Ana. |
Jun 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
309.0K
est: 607.0K (-49.1%)
|
763.0K
est: 2.32M (-67.2%)
|
2.25M
est: 3.67M (-38.8%)
|
12.30M
est: 12.12M (+1.5%)
|
14.90M
est: 14.69M (+1.4%)
|
21.49M
est: 22.75M (-5.5%)
|
22.21M
est: 23.83M (-6.8%)
|
42.80M
est: 42.66M (+0.3%)
|
67.51M
est: 69.45M (-2.8%)
|
60.70M
est: 62.87M (-3.4%)
|
84.32M
est: 82.13M (+2.7%)
|
99.38M
est: 103.60M (-4.1%)
|
101.83M
est: 99.04M (+2.8%)
|
119.73M
est: 119.07M (+0.6%)
|
167.52M
est: 167.43M (+0.0%)
|
171.56M
est: 170.00M (+0.9%)
|
198.93M
est: 191.60M (+3.8%)
|
211.45M
208.79M – 215.11M
+10.4% YoY
|
231.99M
220.30M – 243.09M
+9.7% YoY
|
256.24M
253.24M – 259.23M
+10.5% YoY
|
274.86M
265.97M – 283.99M
+7.3% YoY
|
352.67M
341.26M – 364.39M
+28.3% YoY
|
| EBITDA |
-10.10M
est: 82.9K (-12,279.3%)
|
-9.12M
est: -33.51M (+72.8%)
|
-12.97M
est: -12.90M (-0.5%)
|
-6.05M
est: -39.37M (+84.6%)
|
-4.17M
est: -6.44M (+35.1%)
|
-1.11M
est: -9.23M (+88.0%)
|
-3.90M
est: -2.76M (-41.0%)
|
2.06M
est: -9.85M (+120.9%)
|
15.17M
est: 1.03M (+1,373.4%)
|
7.14M
est: 13.42M (-46.8%)
|
19.21M
est: 8.90M (+115.9%)
|
16.70M
est: 23.49M (-28.9%)
|
15.75M
est: 14.15M (+11.3%)
|
7.86M
est: 17.78M (-55.8%)
|
29.50M
est: 20.43M (+44.4%)
|
21.72M
est: 24.42M (-11.0%)
|
31.82M
est: 36.97M (-13.9%)
|
40.80M
40.28M – 41.50M
+10.4% YoY
|
44.76M
42.50M – 46.90M
+9.7% YoY
|
49.44M
48.86M – 50.01M
+10.5% YoY
|
53.03M
51.31M – 54.79M
+7.3% YoY
|
68.04M
65.84M – 70.30M
+28.3% YoY
|
| EBIT |
-10.52M
est: 56.3K (-18,769.0%)
|
-9.89M
est: -33.51M (+70.5%)
|
-13.98M
est: -12.90M (-8.4%)
|
-6.96M
est: -39.37M (+82.3%)
|
-5.22M
est: -6.44M (+18.9%)
|
-2.08M
est: -9.23M (+77.5%)
|
-4.87M
est: -2.76M (-76.1%)
|
739.0K
est: -9.85M (+107.5%)
|
13.93M
est: -585.7K (+2,478.3%)
|
5.64M
est: 11.63M (-51.5%)
|
17.07M
est: 5.71M (+199.2%)
|
12.80M
est: 20.05M (-36.2%)
|
11.32M
est: 12.46M (-9.2%)
|
2.14M
est: 15.66M (-86.4%)
|
22.37M
est: 18.00M (+24.3%)
|
14.09M
est: 21.51M (-34.5%)
|
23.75M
est: 30.00M (-20.8%)
|
33.11M
32.69M – 33.68M
+10.4% YoY
|
36.32M
34.49M – 38.06M
+9.7% YoY
|
40.12M
39.65M – 40.59M
+10.5% YoY
|
43.04M
41.64M – 44.47M
+7.3% YoY
|
55.22M
53.43M – 57.05M
+28.3% YoY
|
| Net Income |
-8.75M
est: -11.40M (+23.2%)
|
-8.17M
est: -33.51M (+75.6%)
|
-11.21M
est: -12.90M (+13.1%)
|
-4.68M
est: -37.02M (+87.4%)
|
-5.77M
est: -5.67M (-1.7%)
|
-2.61M
est: -9.28M (+71.9%)
|
-5.46M
est: -2.73M (-99.9%)
|
122.0K
est: -9.84M (+101.2%)
|
26.16M
est: 199.0K (+13,043.0%)
|
5.75M
est: 23.65M (-75.7%)
|
13.60M
est: 7.52M (+80.8%)
|
10.14M
est: 17.60M (-42.4%)
|
8.58M
est: 10.83M (-20.8%)
|
3.74M
est: 13.60M (-72.5%)
|
19.88M
est: 19.88M (+0.0%)
|
12.97M
est: 12.97M (+0.0%)
|
20.68M
est: 16.34M (+26.5%)
|
14.30M
13.00M – 15.60M
-12.5% YoY
|
22.92M
17.05M – 25.16M
+60.3% YoY
|
30.68M
13.88M – 33.99M
+33.9% YoY
|
38.33M
36.72M – 39.99M
+24.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
5.73M
est: 323.4K (+1,671.1%)
|
4.93M
est: 1.24M (+298.0%)
|
6.77M
est: 1.96M (+246.2%)
|
7.75M
est: 6.46M (+19.9%)
|
9.18M
est: 14.28M (-35.7%)
|
16.57M
est: 12.12M (+36.7%)
|
18.10M
est: 17.96M (+0.8%)
|
25.36M
est: 36.58M (-30.7%)
|
27.55M
est: 41.37M (-33.4%)
|
32.69M
est: 25.84M (+26.5%)
|
37.81M
est: 42.76M (-11.6%)
|
47.62M
est: 48.91M (-2.6%)
|
53.57M
est: 50.86M (+5.3%)
|
68.16M
est: 63.91M (+6.7%)
|
84.65M
est: 73.46M (+15.2%)
|
92.79M
est: 87.78M (+5.7%)
|
103.97M
est: 111.17M (-6.5%)
|
112.67M
111.25M – 114.62M
+1.3% YoY
|
123.61M
117.38M – 129.53M
+9.7% YoY
|
136.53M
134.94M – 138.13M
+10.5% YoY
|
146.45M
141.72M – 151.32M
+7.3% YoY
|
187.91M
181.84M – 194.16M
+28.3% YoY
|
| EPS |
-0.04
est: -0.04 (-21.0%)
|
-0.04
est: -0.03 (-23.6%)
|
-0.05
est: -0.03 (-48.2%)
|
-0.02
est: -0.03 (+29.6%)
|
-0.02
est: -0.03 (+12.5%)
|
-0.01
est: -0.01 (-16.5%)
|
-0.02
est: -0.02 (+7.7%)
|
0.00
est: 0.00 (-76.3%)
|
0.09
est: 0.04 (+116.8%)
|
0.02
est: 0.01 (+186.6%)
|
0.05
est: 0.03 (+34.0%)
|
0.03
est: 0.04 (-18.0%)
|
0.03
est: 0.02 (+72.9%)
|
0.01
est: -0.01 (+258.1%)
|
0.07
est: 0.05 (+22.7%)
|
0.04
est: 0.03 (+21.7%)
|
0.07
est: 0.06 (+22.3%)
|
0.05
0.04 – 0.05
-14.5% YoY
|
0.07
0.06 – 0.08
+39.2% YoY
|
0.09
0.04 – 0.11
+31.4% YoY
|
0.12
0.12 – 0.13
+42.1% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
62.05M
OE per share TTM
0.20
Owner's Yield
6.46%
Maintenance CapEx ratio
4.49%
Maint CapEx / Avg PPE
12.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | BetaShares - Australian Small Companies Select ETF SMLL.AX | 0.93% | 2.16M | 0.39% |
| 2 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.33% | 291.2K | 0.55% |
| 3 | BetaShares - Australian Sustainability Leaders ETF FAIR.AX | 0.19% | 1.40M | 0.49% |
| 4 | iShares Edge MSCI Australia Multifactor ETF AUMF.AX | 0.17% | 165.4K | 0.30% |
| 5 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.15% | 1.24M | 0.30% |
| 6 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 375.0K | 0.40% |
| 7 | Vanguard Australian Shares Index ETF VAS.AX | 0.03% | 6.09M | 0.07% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 75.2K | 0.30% |
| 9 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.02% | 188.2K | 0.23% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.02% | 188.2K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
51.0K
Shares Outstanding
298.82M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael C. Kavanagh | Chief Executive Officer, President, MD & Executive Director | 1M | male |
| Jason Burriss | Chief Financial Officer | 776.5K | male |
| Rod Lopez | Chief Operating Officer & Regional President for Asia Pacific | 699.8K | male |
| Derek Minihane BSEE | Chief Technology Officer | 582.3K | male |
| Matthew Carbines | General Counsel & Company Secretary | — | male |
| Catherine Strong | Head of Investor Relations & Corporate Communications | — | female |
| Sunny Pillai | Chief Information Officer | — | male |
| Jodi Sampson | Chief People & Culture Officer | — | female |
| Jonathan Burdach | Chief Medical Affairs & Scientific Officer | — | male |
| Kimberly Hill | Chief Marketing Officer & Regional President of Asia Pacific | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NAN.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
